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Abstract
Introduction: We hypothesized that extravascular body fluid (EBF) analysis in Croatia is not harmonized and aimed to investigate preanalytical, 
analytical and postanalytical procedures used in EBF analysis in order to identify key aspects that should be addressed in future harmonization 
attempts.
Materials and methods: An anonymous online survey created to explore laboratory testing of EBF was sent to secondary, tertiary and private 
health care Medical Biochemistry Laboratories (MBLs) in Croatia. Statements were designed to address preanalytical, analytical and postanalytical 
procedures of cerebrospinal, pleural, peritoneal (ascites), pericardial, seminal, synovial, amniotic fluid and sweat. Participants were asked to declare 
the strength of agreement with proposed statements using a Likert scale. Mean scores for corresponding separate statements divided according to 
health care setting were calculated and compared.
Results: The survey response rate was 0.64 (58 / 90). None of the participating private MBLs declared to analyse EBF. We report a mean score of 
3.45 obtained for all statements evaluated. Deviations from desirable procedures were demonstrated in all EBF testing phases. Minor differences in 
procedures used for EBF analysis comparing secondary and tertiary health care MBLs were found. The lowest scores were obtained for statements 
regarding quality control procedures in EBF analysis, participation in proficiency testing programmes and provision of interpretative comments on 
EBF’s test reports.
Conclusions: Although good laboratory EBF practice is present in Croatia, procedures for EBF analysis should be further harmonized to improve the 
quality of EBF testing and patient safety.
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Whole blood, serum, plasma and urine are consid-
ered standard samples submitted for analysis in 
routine laboratory practice. However, occasionally, 
clinical laboratories are requested to perform anal-
yses on a variety of extravascular body fluids (EBF) 
(1,2). EBF have multiple roles: they function as ana-
tomical barriers lubricating the surfaces of lining 
membranes and maintain the homeostasis of or-
gan systems surrounding them. The accumulation 
and/or change in EBF’s composition occur in vari-
ous pathological conditions comprising systemic 
and localized disorders (3). For the purpose of this 
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investigation, the term EBF will apply to cerebro-
spinal fluid (CSF), serous fluids (pleural, peritoneal 
(ascites) and pericardial), synovial fluid, amniotic 
fluid, seminal fluid and sweat (3).
Laboratory testing of EBF involves a wide spec-
trum of analyses with varying clinical utilities. Al-
though considered an important part of disease 
diagnosis and management, it is challenging for 
several reasons including the EBF’s matrix effect, 
lack of commercial assays validated for assessing 
effusions and absence of established reference 
ranges available for EBF testing (3-5).
Several documents issued by the Clinical and Lab-
oratory Standards Institute (CLSI) are of great im-
portance in guiding laboratory professionals 
through EBF laboratory testing (3,6-8), but these 
documents do not address the analysis of each 
specific EBF in the same comprehensive manner. 
Furthermore, national recommendations address-
ing EBF clinical laboratory testing are not available 
in Croatia. However, in 2007, the Croatian Chamber 
of Medical Biochemists (CCMB) issued a document 
comprising a list of recommended methods for 
CSF, synovial, amniotic, seminal, pleural, peritoneal 
fluid and sweat analysis with corresponding refer-
ence ranges and/or clinical decision limits (9). Al-
though in need of revision, this document should 
be considered as benchmark for future national 
harmonization efforts in this field. 
Harmonization of EBF laboratory testing could un-
doubtedly contribute to quality improvement of 
laboratory services and enhance patient safety 
(10). Currently used procedures in EBF analysis in 
Croatian Medical Biochemistry Laboratories (MBLs) 
are largely unknown. Since the first step towards 
harmonization of EBF laboratory testing comprises 
the identification and understanding of differenc-
es among practices, our aim was to investigate 
preanalytical, analytical and postanalytical proce-
dures used in EBF laboratory testing in Croatian 
MBLs. We hypothesized that existing procedures 
are not harmonized and tried to identify key as-
pects that should be addressed in future harmoni-
zation attempts in this field.
Materials and methods
Questionnaire
MBL’s pertaining to secondary (special and general 
hospitals), tertiary (clinics, clinical hospitals and 
clinical hospital centres) and private health care in-
stitutions (MBLs that bill the patient for laboratory 
services provided) were surveyed. These MBLs 
have the authority and competency to perform 
EBF analyses in Croatia. A total of 90 MBL’s were 
identified using the Croatian Society of Medical Bi-
ochemistry and Laboratory Medicine (CSMBLM) 
database. MBL’s managers were invited (by e-mail) 
to participate in an online survey created using the 
survey platform SurveyMonkey (SurveyMonkey 
Inc., Palo Alto, USA). Due to poor response rate in 
the first round (May 2015), members of the Work-
ing group for extravascular body fluids (WG EBF) 
contacted by phone each laboratory manager 
who failed to participate in the first round, briefly 
explaining the aim of the questionnaire and ask-
ing to participate in the survey. Following consent, 
the link for the online survey was mailed to them 
once again. Anonymity was ensured to all survey 
participants. 
The WG EBF questionnaire exploring practices 
used in laboratory testing of EBF was divided in 
nine sections. The first section included questions 
on laboratory type (i.e. health care setting) and 
confirmation of performing EBF laboratory testing. 
MBLs were asked to estimate the average number 
of EBF analysed per year and to identify personnel 
involved in EBF analysis. Furthermore, this section 
included four questions regarding the test request 
form and type of containers used for EBF transport 
to the laboratory.
The remaining eight sections of the survey were 
designed to address the analysis of specific EBF: 
CSF, serous fluids, seminal, synovial, amniotic fluid 
and sweat. Specific EBF sections comprised state-
ments describing selected procedures regarding 
preanalytical, analytical and postanalytical phase 
of EBF analysis. The participants were asked to de-
clare the strength of agreement (i.e. the agree-
ment of EBF analysis procedures performed in 
their laboratories) with each proposed statement 
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in the survey, according to a Likert scale graded as 
1 (never), 2 (rarely), 3 (sometimes), 4 (often) and 5 
(always). The most favourable responses are repre-
sented with the highest score.
Statistical analysis
Qualitative data were presented as counts and 
proportions (N < 100). The number of EBF analyses 
performed yearly was presented as median and 
interquartile range (IQR). Data obtained from the 
Likert scale used in our survey was transformed 
into grades from 1 to 5 (corresponding to grades 
in the Croatian educational system) for compari-
son purposes. Consequently, agreement with indi-
vidual statements was presented as mean score. 
The mean score was calculated for the total group 
of MBLs and for MBLs divided according to health 
care setting (secondary and tertiary health care). 
Differences between qualitative data were tested 
using the Fisher’s exact test (N < 30). Differences in 
mean scores for MBLs divided according to health 
care setting were tested using the Mann-Whitney 
test for independent samples (N < 30). The level of 
significance was set at P < 0.05. Statistical analysis 
was performed using MedCalc, (v 11.5.1, Ostend, 
Belgium).
Results
Fifty-eight MBLs pertaining to secondary and ter-
tiary health care facilities and private laboratories 
participated in the survey. The survey response 
rate was 0.64 (58 / 90). Fourteen MBLs were ex-
cluded from further analysis because of missing 
general characteristics (i.e. respondents failed to 
declare the type of MBL needed for further analy-
sis) and/or did not respond to any question of the 
survey, in spite of acknowledging the performance 
of EBF analysis. Hence, a total of 44 (0.49) surveyed 
private, secondary and tertiary health care Croa-
tian laboratories were included in the analysis.
The distribution of participating MBLs according 
to health care setting is presented in Table 1. None 
of the participating private MBL declared to ana-
lyse EBF. The majority (24 / 29) of the secondary 
and tertiary care MBLs which declared to analyse 
EBF stated that all laboratory personnel (i.e. man-
aging personnel - Master of medical biochemistry 
and Specialists in laboratory medicine, and non-
managing personnel – Bachelor of science in labo-
ratory diagnostics and Medical laboratory techni-
cians) is involved in EBF laboratory testing (data 
not shown). Furthermore, the number EBF ana-
lyzed yearly in surveyed MBLs is presented in Ta-
ble 2. Data on EBF requesting, sampling and trans-
porting are presented in Table 3. 
Category MBLs by health care setting, N = 44
MBLs performing 
EBF analysis, N = 29
Private, N 
(proportion) 7 (0.16) 0 (0)
Secondary, N 
(proportion) 26 (0.59) 20 (0.69)
Tertiary, N 
(proportion) 11 (0.25) 9 (0.31)
MBLs – medical biochemistry laboratories; EBF – extravascular 
body fluid. Secondary health care MBLs comprise laboratories 
located in special and general hospitals. Tertiary health 
care MBLs comprise laboratories located in clinics, clinical 
hospitals and clinical hospital centres. Private laboratories bill 
the customer for laboratory services provided. 








CSF, N (proportion) 26 (0.90) 100 (15–219)
Pleural effusion, N 
(proportion) 28 (0.97) 60 (23–100)
Seminal fluid, N 
(proportion) 8 (0.28) 131 (50–400)
Sweat, N 
(proportion) 10 (0.34) 50 (14–288)
Amniotic fluid, N 
(proportion) 3 (0.10) 10 (10–20)
Synovial fluid, N 
(proportion) 5 (0.17) 5 (2 - 13)
MBLs – medical biochemistry laboratories; EBF – extravascular 
body fluid; CSF – cerebrospinal fluid; IQR – interquartile range.
Table 2. Estimated frequency of EBF analysis performed yearly 
in surveyed MBLs
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Question
Affirmative answers of MBLs by health care setting, N (proportion)
PAll MBLs,
N = 29
Secondary health care 
MBLs,
N = 20
Tertiary health care 
MBLs,
N = 9
Are all the necessary data (comprising the 
patients’ name, date of birth, department, 
physicians’ name, sample type, ordered test) 
clearly stated on the test request?
28 (0.97) 19 (0.95) 9 (1.00) 1.000
Is the patient’s primary diagnosis clearly 
stated on the test request? 19 (0.66) 13 (0.65) 6 (0.67) 1.000
Is the sampling time available on the test 
request? 17 (0.59) 12 (0.60) 5 (0.56) 1.000
Are EBF samples delivered to the laboratory 
exclusively in clean, additive-free 
containers?
22 (0.76) 17 (0.85) 5 (0.56) 0.158
MBLs – medical biochemistry laboratories; EBF – extravascular body fluid. Secondary health care MBLs comprise laboratories 
located in special and general hospitals. Tertiary health care MBLs comprise laboratories located in clinics, clinical hospitals and 
clinical hospital centres.
Differences between secondary and tertiary health care MBLs were calculated using the Fisher’s exact test. P<0.05 was considered 
statistically significant.
Table 3. EBF’s test request and container used for EBF transport
Cerebrospinal fluid
Mean scores for laboratory procedures used in CSF 
analysis obtained from participating MBLs per-
forming CSF analysis are presented in Table 4. The 
lowest mean scores were obtained for statements 
addressing CSF sample delivery, the calculation of 
albumin and immunoglobulin quotients (QAlb and 
QIg) and quality control (QC) procedures instituted 
for CSF analyses. According to the high mean score 
obtained, the STAT panel for CSF analysis generally 
comprises total cell count with morphological 
analysis and total protein, glucose, lactate, chlo-
ride and C-reactive protein (CRP), with differences 
observed in practices between secondary and ter-
tiary health care MBLs (P = 0.025). Total CSF cell 
count is determined manually in the majority of 
the surveyed MBLs. The CSF cell count is reported 
in SI units, with differences observed in practices 
between secondary and tertiary health care MBLs 
(P = 0.039). Similarly, the majority of the participat-
ing MBLs declared to measure the CSF’s total pro-
tein concentration using a pyrogallol red method. 
Participating MBLs often record the delivery time 
of CSF samples to the laboratory (mean score 
4.38). Additionally, they declared that STAT CSF 
analyses are available to the responsible clinician 
in one hour. In general, the type of puncture/sam-
ple type is often specified on the CSF test request. 
A mean score of 3.38 for all laboratory procedures 
used in CSF analysis was obtained.
Serous fluids
Table 5 presents mean scores for procedures used 
in serous fluid analysis, obtained from MBLs which 
declared to perform pleural, peritoneal and peri-
cardial fluid analysis. Concomitant serum samples 
are (only) sometimes delivered with serous fluid 
samples to the laboratory. The majority of MBLs 
declared written procedures for serous fluid labo-
ratory analysis are available to laboratory staff. 
Overall, laboratory testing of pleural fluid in Croa-
tian MBLs comprises fluid’s gross examination fol-
lowed by total protein (TP) and lactate dehydroge-
nase (LD) analysis in both pleural fluid and serum 
sample, as evidenced by the mean total scores ob-
tained. In addition, peritoneal and pericardial fluid 
evaluation comprises albumin analysis. The CCMB 
decision limits for pleural and peritoneal fluid are 
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1. The CSF is delivered to the laboratory 
in three different, clearly identified 
containers.
26 15 (0.58) 1 (0.04) 3 (0.12) 4 (0.15) 3 (0.12) 2.19 2.59 1.44 0.083
2. The type of puncture/sample is 
specified in the test request form. 26 4 (0.15) 2 (0.08) 1 (0.04) 1 (0.04) 18 (0.69) 4.04 3.76 4.56 0.182
3. The delivery time of the sample to the 
laboratory is recorded. 26 3 (0.11) 0 (0) 1 (0.04) 2 (0.08) 20 (0.77) 4.38 4.59 4.00 0.370
4. The STAT panel in CSF testing 
comprises the determination of total 
cell count, morphological analysis of 
cells, and determination of total protein, 
glucose, lactate, chloride and CRP 
concentrations.
26 4 (0.16) 0 (0) 0 (0) 3 (0.12) 19 (0.73) 4.27 4.71 3.44 0.025
5. Total CSF cell count is determined by 
counting the cells in the native sample 
using the Fuchs-Rosenthal’s chamber.
26 2 (0.08) 0 (0) 1 (0.04) 1 (0.04) 22 (0.85) 4.58 4.71 4.33 0.506
6. The total CSF cell count is determined 
using the EBF mode on the automated 
haematology analyser.
25 16 (0.64) 2 (0.08) 0 (0) 2 (0.08) 5 (0.20) 2.12 2.00 2.33 0.586
7. The total CSF cell count is reported as 
number of cells x106 / L. 24 2 (0.08) 0 (0) 0 (0) 1 (0.04) 21 (0.88) 4.63 5.00 4.00 0.039
8. The results of STAT analyses in CSF 
testing are available to clinicians within 
60 minutes upon sample receipt.
25 1 (0.04) 0 (0) 0 (0) 4 (0.16) 20 (0.80) 4.68 4.81 4.44 0.762
9. Total proteins in CSF samples are 
determined using the pyrogallol red 
method.
26 6 (0.23) 0 (0) 0 (0) 0 (0) 20 (0.77) 4.08 4.06 4.11 0.945
10. When calculating the QAlb and QIg, the 
same calibration curve is used for serum 
and CSF parameters.
20 15 (0.75) 0 (0) 0 (0) 0 (0) 5 (0.25) 2.00 1.33 3.00 0.056
11. The laboratory has established an 
internal quality control scheme for total 
CSF cell count.
24 14 (0.58) 1 (0.04) 4 (0.17) 2 (0.08) 3 (0.13) 2.13 2.27 1.89 0.536
12. The laboratory participates in external 
proficiency testing programmes for CSF 
chemistries.
24 21 (0.88) 0 (0) 0 (0) 0 (0) 3 (0.13) 1.50 1.27 1.89 0.335
MBLs – medical biochemistry laboratories; CSF – cerebrospinal fluid; EBF – extravascular body fluid; CRP – C-reactive protein; STAT 
analyses – emergency analyses.
Secondary health care MBLs comprise laboratories located in special and general hospitals. Tertiary health care MBLs comprise 
laboratories located in clinics, clinical hospitals and clinical hospital centres. 
QAlb and QIg - albumin and immunoglobulin quotients. 
Differences between secondary and tertiary health care MBLs were calculated using the Mann-Whitney test for independent 
samples. P<0.05 was considered statistically significant.
Table 4. Distribution of survey responses and comparison of mean scores for procedures used in CSF analysis
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1. Serum samples are always delivered 
to the laboratory in parallel with the 
pleural fluid sample.
25 2 (0.08) 4 (0.16) 9 (0.36) 5 (0.20) 5 (0.20) 3.28 3.24 3.38 0.905
2. Written procedures for preparation 
and analysis of pleural fluid samples 
are available to laboratory staff.
24 4 (0.17) 1 (0.04) 0 (0) 2 (0.08) 17 (0.71) 4.13 4.38 4.63 0.465
3. Pleural fluid analysis includes 
recording its appearance. 25 5 (0.20) 0 (0) 1 (0.04) 1 (0.04) 18 (0.72) 4.08 4.35 3.50 0.378
4. The analysis of pleural fluid 
comprises the determination of 
protein and LD in serum and fluid 
sample.
25 3 (0.12) 1 (0.04) 1 (0.04) 5 (0.20) 15 (0.60) 4.12 4.35 3.63 0.335
5. The laboratory has established 
an internal quality control scheme 
specific for analytes in pleural fluid.
24 5 (0.21) 0 (0) 0 (0) 1 (0.04) 18 (0.75) 4.13 4.24 3.86 0.751
6. The test report contains decision 
limits for pleural fluid analytes 
recommended by the CCMB.
24 9 (0.38) 0 (0) 0 (0) 1 (0.04) 14 (0.58) 3.46 3.53 3.29 0.860
7. Apart from pleural fluid analysis test 
results, the test report also contains 
the interpretation of the results 
obtained (interpretative comment).
24 13 (0.54) 4 (0.17) 4 (0.17) 1 (0.04) 2 (0.08) 1.96 2.24 1.29 0.144
B) PERITONEAL FLUID
1. Serum samples are always delivered 
to the laboratory in parallel with the 
peritoneal fluid sample.
16 2 (0.13) 2 (0.13) 5 (0.31) 4 (0.25) 3 (0.19) 3.25 3.08 3.75 0.425
2. Peritoneal fluid analysis includes 
recording its appearance. 16 3 (0.19) 0 (0) 1 (0.06) 2 (0.13) 10(0.63) 4.00 4.00 4.00 0.738
3. Peritoneal fluid analysis comprises 
the determination of total protein, LD 
and albumin concentrations in serum 
and fluid sample.
16 0 (0) 1 (0.06) 1 (0.06) 4 (0.25) 10 (0.63) 4.44 4.50 4.25 0.546
4. Peritoneal fluid analysis comprises 
the calculation of ascites/serum protein 
ratio and ascites/serum LD ratio.
16 10 (0.63) 1 (0.06) 2 (0.13) 1 (0.06) 2 (0.13) 2.00 1.75 2.75 0.385
5. Methods applied in peritoneal 
fluid analysis are verified for their 
intended use against manufacturer’s 
performance claims.
15 2 (0.13) 0 (0) 1 (0.07) 1 (0.07) 11 (0.73) 4.27 4.00 5.00 0.214
6. Written procedures for preparation 
and analysis of peritoneal fluid 
samples are available to laboratory 
staff.
15 3 (0.20) 0 (0) 0 (0) 0 (0) 12 (0.80) 4.20 4.64 3.00 0.131
Table 5. Distribution of survey responses and comparison of mean scores for procedures used in serous fluid analysis
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7. The test report contains decision 
limits for peritoneal fluid analytes 
recommended by the CCMB.
16 5 (0.31) 1 (0.06) 0 (0) 0 (0) 10 (0.63) 3.56 3.42 4.00 0.637
8. Apart from peritoneal fluid 
analysis test results, the test report 
also contains the interpretation of 
the results obtained (interpretative 
comment).
16 10 (0.63) 1 (0.06) 2 (0.13) 0 (0) 3 (0.19) 2.06 2.42 1.00 0.109
C) PERICARDIAL FLUID
1. Serum samples are always delivered 
to the laboratory in parallel with the 
pericardial fluid sample.
7 0 (0) 1 (0.14) 2 (0.29) 1 (0.14) 3 (0.43) 3.86 3.60 4.50 0.434
2. Written procedures for preparation 
and analysis of pericardial fluid 
samples are available to laboratory 
staff.
7 0 (0) 0 (0) 0 (0) 0 (0) 7 (1.00) 5.00 5.00 5.00 1.000
3. Pericardial fluid analysis comprises 
the determination of total protein, LD 
and albumin concentrations in serum 
and fluid sample.
7 0 (0) 0 (0) 0 (0) 2 (0.29) 5 (0.71) 4.71 4.80 4.50 0.522
4. Apart from pericardial fluid 
analysis test results, the test report 
also contains the interpretation of 
the results obtained (interpretative 
comment).
7 5 (0.71) 0 (0) 0 (0) 0 (0) 2 (0.29) 2.14 2.60 1.00 0.393
MBLs – medical biochemistry laboratories; LD – lactate dehydrogenase; CCMB – Croatian Chamber of Medical Biochemistry.
Secondary health care MBLs comprise laboratories located in special and general hospitals. Tertiary health care MBLs comprise 
laboratories located in clinics, clinical hospitals and clinical hospital centres. 
Differences between secondary and tertiary health care MBLs were calculated using the Mann-Whitney test for independent 
samples. P<0.05 was considered statistically significant.
listed on the majority of test reports. In general, 
similar favourable scores were obtained for proce-
dures used in peritoneal fluid analysis of surveyed 
MBLs, except for the statement regarding the cal-
culation of ascites / serum protein and ascites / se-
rum LD ratio (mean score 1.75). Furthermore, high 
mean total score was obtained for the statement 
regarding the verification of performance claims 
for methods used in peritoneal fluid analysis 
(mean score 4.00). Favourable high mean total 
scores were obtained for all the statements re-
garding pericardial fluid analysis, except for the in-
clusion of an interpretative comment on the peri-
cardial fluid test report. Indeed, all the surveyed 
MBLs rarely include interpretative comments on 
serous fluid test reports for pleural, peritoneal and 
pericardial fluid, respectively. A score of 3.61 for 
laboratory procedures used in serous fluids analy-
sis was obtained. The comparison of scores ob-
tained for MBLs performing serous fluid analysis 
divided according health care setting revealed no 
difference in procedures used. 
Seminal fluid
Mean total scores for procedures used in seminal 
fluid analysis of surveyed MBLs are presented in 
Table 6. MBLs performing seminal fluid analysis 
have written instructions for patient preparation 
and written procedures for sample analysis availa-
ble to laboratory personnel (mean scores 4.86 and 
5.00, respectively). Seminal fluid analysis results 
are usually used in assisted reproductive technol-
ogy procedures. Considering that seminal fluid 
sampling is usually located outside the laboratory, 
majority of MBLs performing seminal fluid analysis 
implemented procedures for the adequate deliv-
ery of seminal fluid sample to the laboratory. Sem-
inal fluid analysis in general comprises evaluation 
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1. Written instructions on how to prepare 
for seminal fluid analysis are available to 
patients.
1 (0.13) 0 (0) 0 (0) 0 (0) 7 (0.88) 4.86 4.83 5.00 0.663
2 Written procedures for preparation and 
analysis of seminal fluid samples are available 
to laboratory staff.
0 (0) 0 (0) 0 (0) 0 (0) 8 (1.00) 5.00 5.00 5.00 1.000
3. Seminal fluid analysis results are used in 
ART procedures. 0 (0) 1 (0.13) 4 (0.50) 2 (0.25) 1 (0.13) 3.38 3.33 3.50 0.733
4. Seminal fluid sampling takes place in a 
room near the laboratory. 4 (0.50) 1 (0.13) 0 (0) 2 (0.25) 1 (0.13) 2.38 2.17 3.00 0.608
5. Procedures for adequate/proper semen 
sample delivery to the laboratory are 
instituted.
0 (0) 0 (0) 1 (0.13) 4 (0.50) 3 (0.37) 4.25 4.17 4.50 0.606
6. Seminal fluid analysis comprises 
determination of fluid appearance, fluid 
volume, liquefaction time, viscosity and pH.
1 (0.13) 0 (0) 1 (0.13) 2 (0.25) 4 (0.50) 4.00 4.50 2.50 0.124
7. Seminal fluid analysis comprises the 
analysis of native semen, sperm analysis, 
sperm vitality analysis, sperm concentration, 
determination of other cells in semen and 
sperm morphology.
0 (0) 0 (0) 0 (0) 2 (0.25) 6 (0.75) 4.75 4.83 4.50 0.445
8. The patient’s therapy is listed on the test 
request. 4 (0.50) 3 (0.38) 1 (0.13) 0 (0) 0 (0) 1.63 1.83 1.00 0.169
9. If very low sperm number is found in 
seminal sample, the sampling error (%SE) is 
reported on the test report.
3 (0.37) 4 (0.50) 0 (0) 1 (0.13) 0 (0) 1.88 2.17 1.00 0.086
10. The test report contains the referent 
ranges for seminal fluid analytes 
recommended by the CCMB.
0 (0) 1 (0.13) 0 (0) 3 (0.33) 4 (0.50) 4.25 4.17 4.50 0.864
11. The test report also contains the 
interpretation of the results obtained 
(interpretative comment).
4 (0.50) 3 (0.38) 0 (0) 1 (0.13) 0 (0) 1.75 2.00 1.00 0.169
12. The laboratory has established an internal 
quality control scheme specific for analytes 
determined in seminal fluid.
4 (0.50) 0 (0) 2 (0.25) 2 (0.25) 0 (0) 2.25 2.17 2.50 0.733
13. The laboratory participates in external 
quality assessment programmes for seminal 
fluid chemistries.
7 (0.87) 0 (0) 1 (0.13) 0 (0) 0 (0) 1.25 1.33 1.00 0.663
MBLs – medical biochemistry laboratories; ART – assisted reproductive technology; CCMB – Croatian Chamber of Medical 
Biochemistry. 
Secondary health care MBLs comprise laboratories located in special and general hospitals. Tertiary health care MBLs comprise 
laboratories located in clinics, clinical hospitals and clinical hospital centres. 
Differences between secondary and tertiary health care MBLs were calculated using the Mann-Whitney test for independent 
samples. P<0.05 was considered statistically significant.
Table 6. Distribution of survey responses and comparison of mean scores for procedures used in seminal fluid analysis
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of fluid appearance, volume, liquefaction time, vis-
cosity and pH, sperm vitality analysis, sperm con-
centration, determination of other cells in semen 
and sperm morphology. Unfavourable total scores 
were obtained for statements regarding the listing 
of the patient’s therapy on the test request, the in-
clusion of interpretative comments on test report 
and the implementation of internal and external 
seminal fluid quality control procedures (mean 
scores 1.63, 1.75, 2.25 and 1.25, respectively). An 
overall score of 3.37 for laboratory procedures 
used in seminal fluid analysis was obtained. No dif-
ference in procedures used in seminal fluid analy-
sis was found comparing secondary and tertiary 
care MBLs. 
Other EBFs
The survey section addressing sweat analysis con-
sisted of 10 statements covering all three phases 
of sweat laboratory testing (including statements 
investigating  methods used, availability of written 
instructions, demographics and analytical details, 
quality control and external quality assessment, 
and reference ranges used. Unfortunately, only 3 
(out of 44) responding MBLs filled out the ques-
tionnaire on sweat testing. Similar questions were 
introduced in sections covering synovial fluid (6 
questions) and amniotic fluid analysis (10 ques-
tions). Only three and two participating MBLs filled 
out the section covering synovial and amniotic flu-
id, respectively. Considering this small sample, the 
statistical analysis for the aforementioned EBF was 
not performed and data on individual statements 
are not presented. 
Discussion
This survey was designed to better understand 
procedures currently used in EBF analysis in Croa-
tia. We were unable to find any similar national 
and international investigation. A mean score of 
3.45 (on a scale from 1 to 5) for all statements can 
be considered an indicator of good laboratory EBF 
practice. Individually, procedures used in serous 
fluids analysis scored 3.61, while procedures for 
CSF and seminal fluid analysis scored 3.38 and 
3.37, respectively. Hence, EBF analysis in Croatia 
could be improved and better harmonized, in all 
the testing phases of EBF analysis. Overall, the 
least favourable responses (evidenced by the low-
est scores) were obtained for statements regard-
ing quality control procedures used for EBF analy-
ses, participation in proficiency testing pro-
grammes for EBF and provision of interpretative 
comments on EBF’s test reports. These results re-
flect the lack of commercially available commuta-
ble EBF control materials and the lack of aware-
ness of interpretative comments as key compo-
nents of clinical counselling and patient manage-
ment (11).
We demonstrated that EBF analysis in Croatia is 
performed in secondary and/or tertiary health 
care MBLs, as was to be expected given the com-
plexity of health care provided in these institu-
tions. According to the survey results, the most 
frequently analysed EBF yearly in Croatian MBLs 
are seminal fluid, CSF and pleural effusions. Re-
quest forms for EBF analysis include extensive pa-
tient identification data along with the ordering 
physicians’ name, EBF type, test ordered and sam-
pling time, meeting regulatory requirements for 
pre-examination processes (7,12,13). We also report 
that EBF are usually delivered to the laboratory in 
clean, additive free containers, which reduces the 
risk of preanalytical error due to inadequate addi-
tive choice and/or contamination. 
The sequential collection of CSF into 3 clearly la-
belled containers is recommended. The first tube 
should be used for chemistry and/or immunology 
testing; the second is intended for microbiology 
and the third/fourth for cellular analysis/cytology 
(7,14,15). According to our results, CSF samples are 
rarely delivered to the laboratory in three different 
containers according to participating MBLs. This 
could be explained by the possible immediate dis-
tribution of CSF samples to pertinent speciality 
laboratories, which are not necessarily part of the 
core (biochemistry) laboratory. Nevertheless, an 
increased risk of erroneous results, particularly in 
samples contaminated with large numbers of red 
blood cells, may be present if CSF samples are not 
properly labelled (16). Although relatively high 
mean scores for statements regarding CSF sample 
delivery time and the specification of type of 
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puncture were obtained, poor adherence to desir-
able preanalytical performance by some partici-
pating MBLs was observed. Therefore, the wide 
implementation of harmonized preanalytical pro-
cedures in CSF sampling and transport could con-
siderably contribute to test results’ reliability. The 
rapid differentiation (and/or exclusion) of acute in-
flammatory diseases of the central nervous system 
(CNS) can be obtained by performing a basic work-
up which we suitably refer to as emergency (STAT) 
CSF test panel (3,17). High mean scores obtained 
for STAT CSF analysis indicates high consistency of 
tests used for CSF screening. Furthermore, the ma-
jority of MBLs surveyed declared to fulfil a STAT 
turnaround time of one hour. CSF cell counts in 
Croatian MBLs are predominantly determined by 
traditional manual method, from native CSF sam-
ples, using a Fuchs-Rosenthal’s chamber and re-
sults reported in SI units. Although both manual 
and automated cell counting methods are recom-
mended by the CCMB and the latter could im-
prove results’ precision, we report rare utilization 
of automated methods in most participating MBLs 
(7,9). This is expected considering the reported 
limitations of such methods (18). High CSF protein 
concentrations are a useful, although nonspecific, 
indicator of meningeal or CNS disease (19). Total 
CSF protein concentrations may be measured us-
ing several sensitive methods. The majority of the 
surveyed MBLs declared to use the pyrogallol red 
method for total CSF protein determination, which 
complies with the CCMB document (9). Inaccuracy 
and imprecision of CSF/serum quotients can be re-
duced only if paired serum and CSF samples are 
analysed within the same run, with the same ana-
lytical method and calibration curve (20,21). Ac-
cording to survey’s results, participating MBLs 
rarely use the same calibration curve for serum 
and CSF parameters in QAlb and QIg calculation. 
The simultaneous sampling of serum and serous 
fluid is necessary for reliable interpretation of se-
rous fluid evaluations’ results (i.e. no reference val-
ues for serous fluid parameters are available). How-
ever, evidence suggests that the reported sam-
pling timing differs significantly (from “obtained 
simultaneously” to “within 24 hours”) (3,22). The 
paired delivery of serous and serum sample is not 
considered standard practice in Croatian MBLs 
surveyed. This is certainly a point that needs clear 
definition and harmonization, regardless the insuf-
ficiency of data to completely understand how the 
time interval between serous fluid and serum 
sampling affects results interpretation (23). 
The majority of surveyed MBLs confirmed availa-
bility of written procedures for serous fluid analy-
sis to laboratory staff. This implies harmonization 
of procedures for serous fluid evaluation within 
corresponding MBLs. Serous effusions are tradi-
tionally differentiated into transudates and exu-
dates to facilitate identification of the underlying 
mechanisms and possible treatment options. Al-
though nonspecific, the evaluation of serous fluid 
appearance is straightforward and can provide 
useful diagnostic information (5,24). The surveyed 
MBLs often include appearance examination in se-
rous fluid analysis, as suggested by the CCMB (9). 
Additionally, they declared to measure protein, LD 
and albumin in serous and serum samples, as evi-
denced by the favourable scores obtained for 
pleural, peritoneal (ascitic) and pericardial fluid. In-
terestingly, MBLs rarely calculate the ascites/serum 
protein ratio and ascites/serum LD ratio as a part 
of peritoneal fluid evaluation. Thus, the diagnostic 
accuracy of peritoneal fluid differentiation is not 
improved by implementation of Light’s criteria 
into routine practice (25,26). In fact, the calculation 
of the aforementioned ratios is not recommended 
by the CCMB in the section addressing peritoneal 
(ascitic) fluid analysis. Conversely, Light’s criteria 
and serum-effusion albumin gradient are listed in 
the same CCMB document for pleural effusions’ 
evaluation (9). The clinical decision limits stated by 
the CCMB are often used in Croatian MBLs for se-
rous fluids differentiation. The lack of manufactur-
er’s specifications for serous fluids obligates the 
laboratory to extensively validate method perfor-
mance for their possible use with these alternative 
matrixes (3,5,19). MBLs surveyed stated that meth-
od verification for peritoneal fluid analysis is often 
performed. Considering all the challenges of such 
verification procedures, we opine that it is more 
likely that the statement regarding method verifi-
cation was misunderstood. Thus, the correspond-
ing score should be interpreted with caution (i.e. 
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the score probably reflects verification of methods 
performed for standard laboratory samples).
In 2010 the fifth edition of “WHO laboratory manu-
al for the examination and processing of human 
semen” was published (27). Although not obliga-
tory, this manual should be regarded as guideline 
for semen analysis. The CCMB harmonization doc-
ument adopted methods and decision limits from 
the WHO manual issued in 1999 (9). Consequently, 
it should be reviewed and updated in light of new 
available evidence. Despite the availability of a 
comprehensive global guideline for seminal fluid 
analysis and results interpretation, our results sug-
gest unsatisfactory harmonization of seminal fluid 
analysis in Croatian MBLs. The majority of sur-
veyed Croatian MBLs have written patients’ in-
structions on how to prepare for seminal fluid 
analysis. This is of utmost importance since semen 
collection procedures may affect usefulness and 
reliability of results (27). Furthermore, written pro-
cedures for seminal fluid analysis are available to 
laboratory staff in most surveyed MBLs. Thus, har-
monization of procedures in seminal fluid analysis 
within the corresponding MBLs can be presumed. 
Semen samples should be collected near the labo-
ratory to minimize sample exposure to tempera-
ture fluctuation and reduce time between collec-
tion and analysis (27). Our results suggest poor ad-
herence of Croatian MBLs to this recommenda-
tion. However, the majority of MBLs surveyed stat-
ed that procedures for adequate sample delivery 
are instituted in their facilities, indicating the MBLs’ 
attempt to minimize the influence of preanalytical 
factors on semen analysis. The majority of the sur-
veyed MBLs analyse traditional semen parameters 
(e.g. appearance, volume, liquefaction etc.) of the 
sperm quality. Drug intake is generally not listed 
on test requests although drugs may influence 
sperm production and quality (28). In assessing 
sperm number and concentration, it is recom-
mended that a total of 400 spermatozoa are 
counted, to obtain a sampling error of less than 
5% (27). Since very low sperm numbers warrant a 
higher sampling error, the test report should in-
clude the calculated sampling error. Our results 
suggest that it is rarely reported by surveyed 
MBLs. The CCMB’s recommended reference rang-
es for seminal fluid analysis are often used in Croa-
tian MBLs, which indicates some degree of results’ 
interpretation harmonization. Unfortunately, these 
ranges are no longer valid and should be replaced 
with new, WHO recommended values. Seminal 
fluid is often used to evaluate the fertility potential 
of a seminal ejaculate as part of assisted reproduc-
tive procedures (29). Thus, the harmonization of 
seminal fluid analysis is important not only for 
MBL, but for in vitro fertilization laboratories as 
well.
EBF, as all “standard” sample types, should be sub-
jected to appropriate quality control procedures 
to ensure reliability of results and patient safety. 
Implementation of quality control (QC) testing is a 
prerequisite for the use of standard assays in EBF 
analysis (3). Unfortunately, quality control is a ma-
jor issue in EBF testing due to scarce availability of 
commutable quality controls and proficiency test-
ing materials. The respective unsatisfactory low 
scores obtained for CSF and seminal fluid analysis 
evidence this. Conversely, the majority of MBLs 
stated that internal QC schemes are established 
for specific pleural fluid analytes. It is our opinion 
that the high score obtained reflects QC proce-
dures used for “standard” sample types and con-
sequently should be interpreted with caution. The 
absence of suitable (i.e. matrix matched) QC mate-
rials should be addressed in future harmonization 
documents and if possible prompt the national 
proficiency testing provider to expand the existing 
scheme to include as many EBF analytes as possi-
ble.
Finally, interpretative comments are an important 
part of the postanalytical phase of laboratory test-
ing. Adding comments to test reports, especially 
when complex test and/or test panels are report-
ed, could enhance the value of laboratory infor-
mation, improve their clinical applicability and ul-
timately patient management (11,30). Laboratory 
testing of EBF can be considered complex for rea-
sons that include preanalytical and analytical is-
sues, lack of comparative values and clinician’s ex-
pertise in this speciality area. Although our results 
suggest low laboratory professionals’ awareness 
of the importance of interpretative commenting in 
EBF testing, it is our opinion that they should play 
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a greater role in this respect. Current develop-
ments in laboratory technology and computer 
networks along with the harmonization of com-
menting should facilitate their use and encourage 
their implementation.
The limitations of our investigation should be ad-
dressed. In order to survey procedures used in lab-
oratory testing of nine different EBF (listed in the 
Introduction), we designed a quite extensive ques-
tionnaire. Unfortunately, even such an extensive 
questionnaire enabled us to survey only selected 
preanalytical, analytical and postanalytical proce-
dures of EBF laboratory testing. This has limited 
the comprehensiveness of obtained results. Addi-
tionally, due to low response rate, our results may 
not represent accurately all Croatian MBLs. Practic-
es used in laboratory testing of EBFs most rarely 
analysed (synovial, amniotic fluid and sweat) were 
not presented nor analysed due low statistical 
strength. Likert scales are widely used in different 
fields for opinion measurement. However, their 
limitation is the possible response distortion re-
sulting in central tendency, acquiescence and so-
cial desirability bias (31). These biases must be tak-
en into consideration when interpreting results 
from Likert scale based surveys. Finally, data were 
self-reported and thus could not be verified inde-
pendently. 
In conclusion, our results confirm that procedures 
used in laboratory testing of EBF in Croatia are not 
harmonized. Deviations from desirable EBF labora-
tory testing procedures were detected in all seg-
ments of the EBF total testing process, but were 
found more pronounced for the following key as-
pects: quality control and/or proficiency testing, 
and interpretative commenting of EBF test results. 
Thus, generation of comprehensive recommenda-
tions related to EBF laboratory testing are urgently 
needed in Croatia. We believe that our results rep-
resent a step closer in achieving harmonization of 
these precious laboratory measurements in an ef-
fort to minimise misinterpretation and adverse pa-
tient outcomes. 
Acknowledgements
The authors would like to thank medical biochem-
istry laboratories who participated in the survey.
Potential conflict of interest
None declared.
 6. Clinical and Laboratory Standards Institute. Sweat te-
sting: Sample collection and quantitative chloride analysis; 
Approved guideline – third edition. CLSI document C34-A3, 
Wayne, Pennsylvania, USA, 2009.
 7. Clinical and Laboratory Standards Institute. Body fluid 
analysis for cellular composition: Approved guideline. CLSI 
document H56-A, Wayne, Pennsylvania, USA, 2006.
 8. Clinical and Laboratory Standards Institute. Assessment 
of fetal lung maturity by the lamellar body count; Appro-
ved guideline. CLSI document C58-A, Wayne, Pennsylvania, 
USA, 2011.
 9. Harmonizacija laboratorijskih nalaza u području opće, spe-
cijalne i visokodiferentne medicinske biokemije. Available 
at: http://www.hkmb.hr/obavijesti/obavijesti-index.html 
(in Croatian). Accessed October 12th 2015.
10. Plebani M. Harmonization in laboratory medicine: the com-
plete picture. Clin Chem Lab Med 2013;51:741–51. http://
dx.doi.org/10.1515/cclm-2013-0075.
References
 1. Wians FH. To test or not to test? Opening Pandora’s box. Lab 
Medicine 2004;35:707. http://dx.doi.org/10.1309/ 3REBHJ-
FAQVLXUQ5W.
 2. Akgul M, Noguez J. Body fluid testing. What you should 




 3. Clinical and Laboratory Standards Institute. Analysis of 
body fluids in clinical chemistry; Approved guideline. CLSI 
document C49-A, Wayne, Pennsylvania, USA, 2007.
 4. Block DR. Practical Guide to the Analytical Validation of Body 
Fluid Chemistry Testing. Available at: http://www.mayo-
medicallaboratories.com/articles/communique/2013/03-
bodyfluid-testing/index.html. Accessed October 25th 2015.
 5. Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and peri-
cardial effusions – a biochemical approach. Biochem Med 
(Zagreb) 2014;24:123-137. http://dx.doi.org/10.11613/
BM.2014.014
http://dx.doi.org/10.11613/BM.2016.042 Biochemia Medica 2016;26(3):395–407 
  407
Milevoj Kopcinovic L. et al. Extravascular body fluids in Croatia
11. Plebani M. Interpretative commenting: A tool for improving 
the laboratory–clinical interface. Clin Chim Acta 2009;404:46-
51. http://dx.doi.org/10.1016/j.cca.2009.03.012.
12. International Organization for Standardization 
15189:2012: Medical laboratories: requirements for quality 
and competence. Geneva, Switzerland, 2012.
13. Standardi dobre stručne prakse. Sadržaj uputnice. Available 
at: http://www.hkmb.hr/povjerenstva/strucna-pitanja.html 
(in Croatian). Accessed October 17th 2015.
14. Strasinger S. Body fluid analysis. In: Bishop ML, Fody EP, 
Schoeff LE, eds. Clinical chemistry techniques, principles, 
correlations. 6th edition. Baltimore, MD and Philadelphia, 
PA: Lippincott Williams and Wilkins; 2010. p. 591-602.
15. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, 
Comabella M, et al. A consensus protocol for the standar-
dization of cerebrospinal fluid collection and biobanking. 
Neurology 2009;73:1914 – 22. http://dx.doi.org/10.1212/
WNL.0b013e3181c47cc2.
16. Deisenhammer F, Bartos, Egg R, Gilhus NE, Giovannoni G, 
Rauer S, et al. Routine cerebrospinal fluid (CSF) analysis. In: 
European Handbook of Neurological Management, 2nd 
edition. Blackwell Publishing, 2011. p. 5-17.
17. Regeniter A, Kuhle J, Mehling M, Möller H, Wurster U, Frei-
danka H, et al. A modern approach to CSF analysis: patho-
physiology, clinical application, proof of concept and labo-
ratory reporting. Clin Neurol Neurosurgery 2009;111:313-
318. http://dx.doi.org/10.1016/j.clineuro.2008.12.004.
18. Li A, Grönlund E, Brattsand G. Automated white blood cell 
counts in cerebrospinal fluid using the body fluid mode 
on the platform Sysmex XE-5000. Scand J Clin Lab Invest 
2014;74:673–80. http://dx.doi.org/10.3109/00365513.2014.
939994.
19. Karcher DS, McPherson RA. Cerebrospinal, synovial, serous 
body fluids and alternative specimens. In: Henry’s clinical di-
agnosis and management by laboratory methods, 22th edi-
tion. Richard A. McPherson, Matthew R. Pincus eds. Elsevier 
Saunders, Philadelphia (PA), 2011. p. 480-506. http://dx.doi.
org/10.1016/b978-1-4377-0974-2.00029-4
20. Reiber H. Reporting Cerebrospinal fluid data: knowledge 





Accessed April 1st 2016. 
21. Reiber H. External quality assessment in clinical neuroche-
mistry: survey of analysis or cerebrospinal (CSF) fluid prote-
ins based on CSF/serum quotients. Clin Chem 1995;441:256-
263.
22. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of te-
sts that discriminate between exudative and transudati-
ve pleural effusions. Chest 1997; 111: 970–80. http://dx.doi.
org/10.1378/chest.111.4.970.
23. Jenkinson F, Murphy MJ. Biochemical analysis of pleural 
and ascitic fluid: effect of sample timing on interpretation 
of results. Ann Clin Biochem 2007;44:471–73. http://dx.doi.
org/10.1258/000456307781645978.
24. Block DR, Algeciras-Schimnich A. Body fluid analysis: Clini-
cal utility and applicability of published studies to guide in-
terpretation of today’s laboratory testing in serous fluids. 
Crit Rev Clin Lab Science 2013;50:107-24. http://dx.doi.org/
10.3109/10408363.2013.844679.
25. Tarn AC, Lapworth R. Biochemical analysis of ascetic (pe-
ritoneal) fluid: what should we measure? Ann Clin Bi-
ochem 2010;47:397-407. http://dx.doi.org/10.1258/
acb.2010.010048.
26. Burgess LJ. Biochemical analysis of pleural, peritoneal and 
pericardial effusions. Clin Chim Acta 2004;343:61-84. http://
dx.doi.org/10.1016/j.cccn.2004.02.002.
27. World Health Organization. WHO laboratory manual for 
the examination and processing of human semen. 5th ed., 
2010.
28. Samplaski MK, Nangia AK. Adverse effects of common 
medications on male fertility. Nature Reviews Urology 
2015;12:401-13. http://dx.doi.org/10.1038/nrurol.2015.145. 
29. Agarwal A, Said TM. Interpretation of basic semen analysis 
and advanced semen testing. In: Current Clinical Urology: 
Male Infertility: Problems and Solutions, Edited by: Saba-
negh ES, Springer Science and Business Media, 2011. http://
dx.doi.org/10.1007/978-1-60761-193-6_2.
30. Lim EM, Sikaris KA, Gill J, Calleja J, Hickman PE, Beilby J, Va-
sikaran SD. Quality assessment of interpretative commen-
ting in clinical chemistry. Clin Chem 2004;50:632-37. http://
dx.doi.org/10.1373/clinchem.2003.024877.
31. Rinker T. On the treatment of Likert data. Available from: 
https://www.researchgate.net/publication/262011454_Li-
kert. Accessed August 14th 2016.
